1
|
Zhang C, Bodmeier R. Porous PLGA microparticles prepared with nanosized/micronized sugar particles as porogens. Int J Pharm 2024; 660:124329. [PMID: 38857662 DOI: 10.1016/j.ijpharm.2024.124329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 06/06/2024] [Accepted: 06/07/2024] [Indexed: 06/12/2024]
Abstract
The objective of this study was to explore the use of nanosized/micronized sugar particles as porogens for preparing porous poly(lactide-co-glycolide) (PLGA) microparticles by a solid-in-oil-in-water (S/O/W) solvent evaporation method. Porous PLGA microparticles containing dexamethasone were prepared with different nanosized/micronized sugars (sucrose, trehalose and lactose), types of PLGA, and osmogens (NaCl or sucrose) in the external water phase. The microparticles were characterized for morphology, thermal properties, particle size, surface area, encapsulation efficiency and drug release/swelling during release. The addition of nanosized/micronized sugar particles resulted in porous PLGA microparticles with high encapsulation efficiencies. The porosity of the microparticles was caused both by the influx of water into the polymer droplets and the encapsulation and subsequent dissolution of sugar particles during the manufacturing process. The porosity (pore size) of the microparticles and, as a result, the drug release pattern could be well controlled by the particle size and weight fraction of the sugar particles. Because of a larger inner surface area, nanosized sugar particles were more efficient porogen than micronized sugar particles to obtain porous PLGA microparticles with flexible release patterns.
Collapse
Affiliation(s)
- Chenghao Zhang
- College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany
| | - Roland Bodmeier
- College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
| |
Collapse
|
2
|
Khan MRH, Armstrong Z, Lenertz M, Saenz B, Kale N, Li Q, MacRae A, Yang Z, Quadir M. Metal-Organic Framework Induced Stabilization of Proteins in Polymeric Nanoparticles. ACS APPLIED MATERIALS & INTERFACES 2024. [PMID: 38490971 DOI: 10.1021/acsami.3c16534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/18/2024]
Abstract
Developing protein confinement platforms is an attractive research area that not only promotes protein delivery but also can result in artificial environment mimicking of the cellular one, impacting both the controlled release of proteins and the fundamental protein biophysics. Polymeric nanoparticles (PNPs) are attractive platforms to confine proteins due to their superior biocompatibility, low cytotoxicity, and controllable release under external stimuli. However, loading proteins into PNPs can be challenging due to the potential protein structural perturbation upon contacting the interior of PNPs. In this work, we developed a novel approach to encapsulate proteins in PNPs with the assistance of the zeolitic imidazolate framework (ZIF). Here, ZIF offers an additional protection layer to the target protein by forming the protein@ZIF composite via aqueous-phase cocrystallization. We demonstrated our platform using a model protein, lysozyme, and a widely studied PNP composed of poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA). A comprehensive study via standard loading and release tests as well as various spectroscopic techniques was carried out on lysozyme loaded onto PEG-PLGA with and without ZIF protection. As compared with the direct protein encapsulation, an additional layer with ZIF prior to loading offered enhanced loading capacity, reduced leaching, especially in the initial stage, led to slower release kinetics, and reduced secondary structural perturbation. Meanwhile, the function, cytotoxicity, and cellular uptake of proteins encapsulated within the ZIF-bound systems are decent. Our results demonstrated the use of ZIF in assisting in protein encapsulation in PNPs and established the basis for developing more sophisticated protein encapsulation platforms using a combination of materials of diverse molecular architectures and disciplines. As such, we anticipate that the protein-encapsulated ZIF systems will serve as future polymer protein confinement and delivery platforms for both fundamental biophysics and biochemistry research and biomedical applications where protein delivery is needed to support therapeutics and/or nutrients.
Collapse
Affiliation(s)
- Md Rakib Hasan Khan
- Biomedical Engineering Program, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Zoe Armstrong
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Mary Lenertz
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Briana Saenz
- Department of Chemistry and Biochemistry, St. Mary's University, San Antonio, Texas 78228, United States
| | - Narendra Kale
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Qiaobin Li
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Austin MacRae
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Zhongyu Yang
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108, United States
| | - Mohiuddin Quadir
- Biomedical Engineering Program, North Dakota State University, Fargo, North Dakota 58108, United States
- Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, North Dakota 58108, United States
| |
Collapse
|
3
|
Bassand C, Siepmann F, Benabed L, Verin J, Freitag J, Charlon S, Soulestin J, Siepmann J. 3D printed PLGA implants: How the filling density affects drug release. J Control Release 2023; 363:1-11. [PMID: 37714435 DOI: 10.1016/j.jconrel.2023.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 07/22/2023] [Accepted: 09/10/2023] [Indexed: 09/17/2023]
Abstract
Different types of ibuprofen-loaded, poly (D,L lactic-co-glycolic acid) (PLGA)-based implants were prepared by 3D printing (Droplet Deposition Modeling). The theoretical filling density of the mesh-shaped implants was varied from 10 to 100%. Drug release was measured in agarose gels and in well agitated phosphate buffer pH 7.4. The key properties of the implants (and dynamic changes thereof upon exposure to the release media) were monitored using gravimetric measurements, optical microscopy, Differential Scanning Calorimetry, Gel Permeation Chromatography, and Scanning Electron Microscopy. Interestingly, drug release was similar for implants with 10 and 30% filling density, irrespective of the experimental set-up. In contrast, implants with 100% filling density showed slower release kinetics, and the shape of the release curve was altered in agarose gels. These observations could be explained by the existence (or absence) of a continuous aqueous phase between the polymeric filaments and the "orchestrating role" of substantial system swelling for the control of drug release. At lower filling densities, it is sufficient for the drug to be released from a single filament. In contrast, at high filling densities, the ensemble of filaments acts as a much larger (more or less homogeneous) polymeric matrix, and the average diffusion pathway to be overcome by the drug is much longer. Agarose gel (mimicking living tissue) hinders substantial PLGA swelling and delays the onset of the final rapid drug release phase. This improved mechanistic understanding of the control of drug release from PLGA-based 3D printed implants can help to facilitate the optimization of this type of advanced drug delivery systems.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - S Charlon
- IMT Lille Douai, Dept Polymers & Composites Technol & Mech Engn, F-59500 Douai, France
| | - J Soulestin
- IMT Lille Douai, Dept Polymers & Composites Technol & Mech Engn, F-59500 Douai, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
4
|
Bannigan P, Bao Z, Hickman RJ, Aldeghi M, Häse F, Aspuru-Guzik A, Allen C. Machine learning models to accelerate the design of polymeric long-acting injectables. Nat Commun 2023; 14:35. [PMID: 36627280 PMCID: PMC9832011 DOI: 10.1038/s41467-022-35343-w] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 11/28/2022] [Indexed: 01/11/2023] Open
Abstract
Long-acting injectables are considered one of the most promising therapeutic strategies for the treatment of chronic diseases as they can afford improved therapeutic efficacy, safety, and patient compliance. The use of polymer materials in such a drug formulation strategy can offer unparalleled diversity owing to the ability to synthesize materials with a wide range of properties. However, the interplay between multiple parameters, including the physicochemical properties of the drug and polymer, make it very difficult to intuitively predict the performance of these systems. This necessitates the development and characterization of a wide array of formulation candidates through extensive and time-consuming in vitro experimentation. Machine learning is enabling leap-step advances in a number of fields including drug discovery and materials science. The current study takes a critical step towards data-driven drug formulation development with an emphasis on long-acting injectables. Here we show that machine learning algorithms can be used to predict experimental drug release from these advanced drug delivery systems. We also demonstrate that these trained models can be used to guide the design of new long acting injectables. The implementation of the described data-driven approach has the potential to reduce the time and cost associated with drug formulation development.
Collapse
Affiliation(s)
- Pauric Bannigan
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada
| | - Zeqing Bao
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada
| | - Riley J Hickman
- Department of Computer Science, University of Toronto, Toronto, ON, M5S 3H6, Canada
- Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, ON, M5S 3E5, Canada
- Vector Institute for Artificial Intelligence, Toronto, ON, M5S 1M1, Canada
| | - Matteo Aldeghi
- Department of Computer Science, University of Toronto, Toronto, ON, M5S 3H6, Canada
- Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, ON, M5S 3E5, Canada
- Vector Institute for Artificial Intelligence, Toronto, ON, M5S 1M1, Canada
| | - Florian Häse
- Department of Computer Science, University of Toronto, Toronto, ON, M5S 3H6, Canada
- Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, ON, M5S 3E5, Canada
- Vector Institute for Artificial Intelligence, Toronto, ON, M5S 1M1, Canada
| | - Alán Aspuru-Guzik
- Department of Computer Science, University of Toronto, Toronto, ON, M5S 3H6, Canada.
- Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, ON, M5S 3E5, Canada.
- Vector Institute for Artificial Intelligence, Toronto, ON, M5S 1M1, Canada.
- Department of Materials Science & Engineering, University of Toronto, Toronto, ON, M5S 3E4, Canada.
- Lebovic Fellow, Canadian Institute for Advanced Research, Toronto, ON, M5S 1M1, Canada.
- CIFAR Artificial Intelligence Research Chair, Vector Institute, Toronto, ON, M5S 1M1, Canada.
| | - Christine Allen
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada.
| |
Collapse
|
5
|
How agarose gels surrounding PLGA implants limit swelling and slow down drug release. J Control Release 2022; 343:255-266. [PMID: 35085697 DOI: 10.1016/j.jconrel.2022.01.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 01/12/2022] [Accepted: 01/19/2022] [Indexed: 11/20/2022]
Abstract
The aim of this study was to better understand to which extent and in which way the presence of an agarose gel (mimicking living tissue) around a PLGA [poly(lactic-co-glycolic acid)] implant affects the resulting drug release kinetics. Ibuprofen-loaded implants were prepared by hot melt extrusion. Drug release was measured upon exposure to phosphate buffer pH 7.4 in Eppendorf tubes, as well as upon inclusion into an agarose gel which was exposed to phosphate buffer pH 7.4 in an Eppendorf tube or in a transwell plate. Dynamic changes in the implants' dry & wet mass and dimensions were monitored gravimetrically and by optical macroscopy. Implant erosion and polymer degradation were observed by SEM and GPC. Different pH indicators were used to measure pH changes in the bulk fluids, gels and within the implants during drug release. Ibuprofen release was bi-phasic in all cases: A zero order release phase (~20% of the dose) was followed by a more rapid, final drug release phase. Interestingly, the presence of the hydrogel delayed the onset of the 2nd release phase. This could be attributed to the sterical hindrance of implant swelling: After a certain lag time, the degrading PLGA matrix becomes sufficiently hydrophilic and mechanically instable to allow for the penetration of substantial amounts of water into the system. This fundamentally changes the conditions for drug release: The latter becomes much more mobile and is more rapidly released. A gel surrounding the implant mechanically hinders system swelling and, thus, slows down drug release. These observations also strengthen the hypothesis of the "orchestrating" role of PLGA swelling for the control of drug release and can help developing more realistic in vitro release set-ups.
Collapse
|
6
|
Ma Z, Liu J, Li X, Xu Y, Liu D, He H, Wang Y, Tang X. Hydroxycamptothecin (HCPT)-loaded PEGlated lipid-polymer hybrid nanoparticles for effective delivery of HCPT: QbD-based development and evaluation. Drug Deliv Transl Res 2022; 12:306-324. [PMID: 33712991 DOI: 10.1007/s13346-021-00939-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/04/2021] [Indexed: 11/27/2022]
Abstract
Lipid-polymer hybrid nanoparticles (LPNs) are promising drug delivery systems in various of disease treatment areas, particularly for cancer treatments. Here, a water-insoluble antitumor agent, hydroxycamptothecin (HCPT), was successfully incorporated into LPNs formed from polylactic-co-glycolic acid (PLGA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000) (DSPE-PEG2000), and lecithin, by a modified single emulsification-solvent evaporation method. Quality-by-design (QbD) strategy composed of Plackett-Burman and Box-Behnken designs were applied for optimizing HCPT-LPNs with desired properties. The optimized HCPT-loaded lipid-polymer hybrid nanoparticles (HCPT-LPNs) were on the nanoscale, with a final size of 220.9 nm, drug loading of 2.50%. HCPT-LPNs were highly stable in plasma and had pH- and drug loading-related sustained release characteristics. The in vitro cytotoxicity of HCPT-LPNs against MCF-7 and HepG2 cells showed that HCPT-LPNs had higher in vitro cytotoxicity than HCPT solution (HCPT-Sol) with reduced cell viability and IC50 values. In vivo pharmacokinetic assays demonstrated that the AUC of HCPT-LPNs was more than 3 times higher than that of HCPT-Sol after tail vein injection in SD rats. Tumor growth was significantly inhibited compared with HCPT-Sol after a single tail vein injection of HCPT-LPNs in murine LLC-GFP-luc lung cancer bearing mice at a dose of 6 mg/kg, without severe side effects. These results indicate that HCPT-LPNs are the promising drug delivery system for antitumor treatments.
Collapse
Affiliation(s)
- Ziwei Ma
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Jingjing Liu
- The First Affliated Hospital of Jinzhou Medical University, No. 2, 5th Section of Renmin Street, Jinzhou, China
| | - Xiaowen Li
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Ying Xu
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Dongchun Liu
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Haibing He
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Yanjiao Wang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China
| | - Xing Tang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road, No. 103, Shenyang, China.
| |
Collapse
|
7
|
Wu J, Xu S, Han CC, Yuan G. Controlled drug release: On the evolution of physically entrapped drug inside the electrospun poly(lactic-co-glycolic acid) matrix. J Control Release 2021; 331:472-479. [PMID: 33549717 DOI: 10.1016/j.jconrel.2021.01.038] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 01/26/2021] [Accepted: 01/27/2021] [Indexed: 11/16/2022]
Abstract
The drug loading and releasing properties of poly(lactic-co-glycolic acid) (PLGA) were approached with the application of neutron techniques. The neutron reflection (NR) study on the response of PLGA material to vapor and to bulk water revealed that the hydration of PLGA origins from the molecular compatibility between water and PLGA. Hydration is reversible with regard to the change in humidity and temperature. Capecitabine as drug was embedded in the electrospun PLGA fibers. Small angle neutron scattering (SANS) was able to disclose the domain of entrapped drug inside the fibers and trace its evolution over time when the electrospun membrane was incubated in D2O buffer solution. The evolution of drug domains is discussed in terms of the concentration dependence, the temperature dependence, and the relevance between the drug diffusion inside the polymer matrix and the drug release out to the medium. It was observed that, at 20 °C the drug-related domains are relatively small (~ 100 Å) and relax extremely slow while at 37 °C the drug-related domains are relatively larger (~ 200 Å) and relax faster. These behaviors can be related to the glassy property of structural material. The transportation of drug through the polymer matrix relies on the global relaxation of PLGA chains. The variation of fiber diameter vs. incubation time was followed by ultra-small angle neutron scattering (USANS). The bi-phasic or tri-phasic release kinetics from a series of fibers with different drug loading (2%, 5%, 10%, 20%, 30%, 40%, 50%) were discussed based on the SANS and USANS discovery.
Collapse
Affiliation(s)
- Jiaen Wu
- Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China
| | - Shanshan Xu
- Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China; Materials Science and Engineering, University of Maryland, College Park, MD 20742, USA.
| | - Charles C Han
- Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China; Materials Science and Engineering, University of Maryland, College Park, MD 20742, USA
| | - Guangcui Yuan
- Center for Neutron Research, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA; Department of Physics, Georgetown University, Washington, D. C., 20057, USA.
| |
Collapse
|
8
|
Tamani F, Bassand C, Hamoudi M, Siepmann F, Siepmann J. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures. Int J Pharm 2021; 596:120220. [DOI: 10.1016/j.ijpharm.2021.120220] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Revised: 12/22/2020] [Accepted: 12/25/2020] [Indexed: 12/27/2022]
|
9
|
Tamani F, Hamoudi MC, Danede F, Willart J, Siepmann F, Siepmann J. Towards a better understanding of the release mechanisms of caffeine from PLGA microparticles. J Appl Polym Sci 2020. [DOI: 10.1002/app.48710] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Fahima Tamani
- Univ. Lille, Inserm, CHU Lille, U1008, Lille, F‐59000 France
| | | | - Florence Danede
- Univ. Lille, USTL UMET UMR CNRS 8207, F‐59650 Villeneuve d'Ascq France
| | | | | | | |
Collapse
|
10
|
Tamani F, Bassand C, Hamoudi MC, Danede F, Willart JF, Siepmann F, Siepmann J. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Diprophylline dispersions. Int J Pharm 2019; 572:118819. [PMID: 31726196 DOI: 10.1016/j.ijpharm.2019.118819] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 10/17/2019] [Accepted: 10/21/2019] [Indexed: 01/29/2023]
Abstract
The aim of this study was to better understand the root causes for the (up to) 3 drug release phases observed with poly (lactic-co-glycolic acid) (PLGA) microparticles containing diprophylline particles: The 1st release phase ("burst release"), 2nd release phase (with an "about constant release rate") and 3rd release phase (which is again rapid and leads to complete drug exhaust). The behavior of single microparticles was monitored upon exposure to phosphate buffer pH 7.4, in particular with respect to their drug release and swelling behaviors. Diprophylline-loaded PLGA microparticles were prepared with a solid-in-oil-in-water solvent extraction/evaporation method. Tiny drug crystals were rather homogeneously distributed throughout the polymer matrix after manufacturing. Batches with "small" (63 µm), "medium-sized" (113 µm) and "large" (296 µm) microparticles with a practical drug loading of 5-7% were prepared. Importantly, each microparticle releases the drug "in its own way", depending on the exact distribution of the tiny drug crystals within the system. During the burst release, drug crystals with direct surface access rapidly dissolve. During the 2nd release phase tiny drug crystals (often) located in surface near regions which undergo swelling, are likely released. During the 3rd release phase, the entire microparticle undergoes substantial swelling. This results in high quantities of water present throughout the system, which becomes "gel-like". Consequently, the drug crystals dissolve, and the dissolved drug molecules rather rapidly diffuse through the highly swollen polymer gel.
Collapse
Affiliation(s)
- F Tamani
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - M C Hamoudi
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Danede
- Univ. Lille, USTL UMET UMR CNRS 8207, F-59650 Villeneuve d'Ascq, France
| | - J F Willart
- Univ. Lille, USTL UMET UMR CNRS 8207, F-59650 Villeneuve d'Ascq, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
11
|
Often neglected: PLGA/PLA swelling orchestrates drug release: HME implants. J Control Release 2019; 306:97-107. [DOI: 10.1016/j.jconrel.2019.05.039] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 05/13/2019] [Accepted: 05/26/2019] [Indexed: 11/22/2022]
|
12
|
Mylonaki I, Allémann E, Delie F, Jordan O. Imaging the porous structure in the core of degrading PLGA microparticles: The effect of molecular weight. J Control Release 2018; 286:231-239. [DOI: 10.1016/j.jconrel.2018.07.044] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 07/06/2018] [Accepted: 07/27/2018] [Indexed: 12/12/2022]
|
13
|
Wang P, Li Y, Jiang M. Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system. Colloids Surf B Biointerfaces 2018; 171:85-93. [PMID: 30015142 DOI: 10.1016/j.colsurfb.2018.04.063] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 04/28/2018] [Accepted: 04/30/2018] [Indexed: 02/08/2023]
Abstract
Traditional polypeptide-loaded PLGA microspheres (PM) using emulsion electrospray techniques often exhibit unsteady release and limited bioactivity. To solve these two problems, an Exenatide (EXT)-loaded multilayer system composed ofPM and thermosensitive hydrogel was prepared by the emulsion electrospray technique in this study. Hydrogel mixture were loaded in PLGA microspheres as Depot-hydrogel to prepare Gel/PM. The PM/Gel and Gel/PM/Gel systems were obtained by dispersion of PM and Gel/PM into hydrogel mixture, respectively. EXT in Gel/PM/Gel showed a constantly in vitro release for 30 days, which was significantly enhanced in comparison of those in the PM/Gel and the Gel/PM. PM/Gel and Gel/PM/Gel showed diminished burst release and no platform period compared with PM and Gel/PM. And these could be because the introduced Matrix-hydrogel outside, as a buffer layer, inhibited burst releases and exhibited a sustained manner. The inner Depot-hydrogelstructure slowed the PLGA degradation rate and drug release rate. As well, more than 15-day blood glucose levels in KKAy mice were greatly maintained at 7.50-9.50 mmol/L after a single subcutaneous injection of Gel/PM/Gel (4.95 μg/kg). Spatial stability and further bioactivity of released EXT were well protected by EXT-hydrogel complexes, and undesirable uptake of EXT and microspheres via phagocytes were also decreased by PEG shell. Thus, the long-acting microspheres/hydrogel multilayer system prepared by emulsion electrospray technique showed promising potentials for loading hydrophilic polypeptides and proteins.
Collapse
Affiliation(s)
- Puxiu Wang
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China; Department of the First Clinical Pharmacy, China Medical University, Shenyang, Liaoning, PR China.
| | - Yue Li
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China.
| | - Mingyan Jiang
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China.
| |
Collapse
|
14
|
Wang P, Zhuo X, Chu W, Tang X. Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity. Int J Pharm 2017; 528:62-75. [DOI: 10.1016/j.ijpharm.2017.05.069] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Revised: 05/29/2017] [Accepted: 05/29/2017] [Indexed: 12/17/2022]
|
15
|
Lin X, Wang J, Xu Y, Tang X, Chen J, Zhang Y, Zhang Y, Yang Z. Tracking the effect of microspheres size on the drug release from a microsphere/sucrose acetate isobutyrate (SAIB) hybrid depotin vitroandin vivo. Drug Dev Ind Pharm 2016; 42:1455-65. [DOI: 10.3109/03639045.2016.1143952] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
16
|
Ahmed TA, Alharby YA, El-Helw ARM, Hosny KM, El-Say KM. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. Drug Des Devel Ther 2016; 10:405-15. [PMID: 26855565 PMCID: PMC4725642 DOI: 10.2147/dddt.s98078] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
This study aimed to develop an optimized depot injectable atorvastatin (ATR) biodegradable in situ gel (ISG) system with minimum initial burst using a central composite design. The factors selected were poly (d, l-lactide-co-glycolide) (PLGA) concentration (X1), molecular weight of polyethylene glycol (PEG) (X2), and PEG concentration (X3). The independent variables were the initial burst of ATR after 2 (Y1) and 24 hours (Y2). The optimized formulation was investigated using scanning electron microscopy, Fourier transform infrared spectroscopy, and in vitro drug release in phosphate-buffered saline of pH 7.4 for 72 hours. The in vivo pharmacokinetic study of the optimized ATR-ISG and the corresponding PEG-free ATR-ISG were conducted by intramuscular injection of a single dose (2 mg/kg) of ATR in male New Zealand White rabbits. A double-blind, randomized, parallel design was used in comparison with those of the marketed ATR tablet. Statistical analysis revealed that PLGA concentration and the molecular weight of PEG have pronounced effects on both Y1 and Y2. The optimized formulation was composed of 36.10% PLGA, PEG 6000, and 15.69% PEG, and exhibited characteristic in vitro release pattern with minimal initial burst. Incorporation of PEG in the formulation causes a slight decrease in the glass transition temperature value of PLGA, leading to a slight change in Fourier transform infrared spectroscopy spectrum due to possible interaction. Moreover, scanning electron microscopy photomicrograph showed smooth surface with disappearance of the cracks which characterize the surface of PEG-free formulation. The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet. The optimized ATR-ISG formulation has shown minimal initial drug burst which confirms the suitability of the ISG system in the prolongation of drug release in patients with chronic long-term therapy.
Collapse
Affiliation(s)
- Tarek A Ahmed
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
| | - Yasser A Alharby
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Abdel-Rahim M El-Helw
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Khaled M Hosny
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni Suef University, Beni Suef, Egypt
| | - Khalid M El-Say
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
| |
Collapse
|
17
|
Gasmi H, Danede F, Siepmann J, Siepmann F. Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies. J Control Release 2015; 213:120-127. [DOI: 10.1016/j.jconrel.2015.06.039] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 06/27/2015] [Accepted: 06/29/2015] [Indexed: 12/11/2022]
|
18
|
Lin X, Xu Y, Tang X, Zhang Y, Chen J, Zhang Y, He H, Yang Z. A Uniform Ultra-Small Microsphere/SAIB Hybrid Depot with Low Burst Release for Long-Term Continuous Drug Release. Pharm Res 2015; 32:3708-21. [PMID: 26077999 DOI: 10.1007/s11095-015-1731-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 06/01/2015] [Indexed: 01/14/2023]
Abstract
PURPOSE In the present study, a uniform ultra-small microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot (m-SAIB depot) was designed to provide a long-term sustained release drug delivery system which not only reduced the burst release of an SAIB depot, but also eliminated the lag-time of PLGA microspheres. METHODS Risperidone loaded m-SAIB depot (Ris-m-SAIB depot) was characterized by in vitro drug release, pharmacokinetics, in vivo degradation and biocompatibility, in comparison with risperidone loaded SAIB depot (Ris-SAIB depot). RESULTS Ris-m-SAIB depot showed a low burst release (0.64%) and a reduced in vitro drug release rate due to the encapsulation of most drug in microspheres. After intramuscular administration, the in vivo burst release of Ris-m-SAIB was significantly decreased, as reflected by the low Cmax/Cs(4-td) (approximately 30-fold reduction), in comparison with Ris-SAIB depot. From 4 to 78 days, Ris-m-SAIB depot showed a higher plasma drug level (1.55 ~ 16.30 ng/ml) with a steadier drug release profile compared with Ris-SAIB depot. Ris-m-SAIB depot degraded gradually with a degradation t1/2 of 54.6 days and exhibited good biocompatibility in vivo. CONCLUSION These results demonstrate the potential application of a uniform ultra-small microsphere/SAIB hybrid depot for continuously delivering small drug molecules for long periods of time without burst release.
Collapse
Affiliation(s)
- Xia Lin
- School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China.
- School of Pharmaceutical Science, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, People's Republic of China.
| | - Yuhong Xu
- School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China
| | - Xing Tang
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, People's Republic of China
| | - Yan Zhang
- Normal College, Shenyang University, Shenyang, 110044, People's Republic of China
| | - Jian Chen
- School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China
| | - Yu Zhang
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, People's Republic of China
| | - Haibing He
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, People's Republic of China
| | - Ziyi Yang
- School of Pharmaceutical Science, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, People's Republic of China.
| |
Collapse
|
19
|
Abstract
Due mainly to their poor stability and short plasma half-life, peptides are usually administered by injection, often several times daily. Injectable sustained-release formulations of peptides based on biodegradable polymer microparticles or implants early demonstrated the power of drug delivery technologies to enhance patient adherence and convenience, and increase safety and efficacy. Injectable sustained-release formulations are likely to remain a significant part of new peptide products. However, a new generation of technologies that enable solvent-free formulations and manufacturing processes, injection through narrow gauge needles and ready-to-use presentations will be increasingly used. In addition, the tremendous developments in noninvasive routes of delivery are likely to result in more and more peptides being delivered by the oral, transdermal, nasal or inhalation routes.
Collapse
|
20
|
Vesna Milacic VM, Schwendeman SP. Lysozyme release and polymer erosion behavior of injectable implants prepared from PLGA-PEG block copolymers and PLGA/PLGA-PEG blends. Pharm Res 2014; 31:436-48. [PMID: 23959854 PMCID: PMC3930621 DOI: 10.1007/s11095-013-1173-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 07/28/2013] [Indexed: 11/29/2022]
Abstract
PURPOSE We evaluated the controlled release of lysozyme from various poly(D,L-lactic-co-glycolic acid) (PLGA) 50/50-polyethylene glycol (PEG) block copolymers relative to PLGA 50/50. METHODS Lysozyme was encapsulated in cylindrical implants (0.8 mm diameter) by a solvent extrusion method. Release studies were conducted in phosphate buffered saline +0.02% Tween 80 (PBST) at 37°C. Lysozyme activity was measured by a fluorescence-based assay. Implant erosion was evaluated by kinetics of polymer molecular weight decline, water uptake, and mass loss. RESULTS Lysozyme release from an AB15 di-block copolymer (15% 5 kDa PEG, PLGA 28 kDa) was very fast, whereas an AB10 di-block copolymer (with 10% 5 kDa PEG, PLGA 45 kDa) and ABA10 tri-block copolymer (with 10% 6 kDa PEG, PLGA 27 kDa) showed release profiles similar to PLGA. We achieved continuous lysozyme release for up to 4 weeks from AB10 and ABA10 by lysozyme co-encapsulation with the pore-forming and acid-neutralizing MgCO3, and from AB15 by co-encapsulation of MgCO3 and blending AB15 with PLGA. Lysozyme activity was mostly recovered during 4 weeks. CONCLUSIONS These block co-polymers may have utility either alone or as PLGA blends for the controlled release of proteins.
Collapse
|
21
|
Mashayekhi R, Mobedi H, Najafi J, Enayati M. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. Daru 2013; 21:57. [PMID: 23856431 PMCID: PMC3737027 DOI: 10.1186/2008-2231-21-57] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 06/11/2013] [Indexed: 11/10/2022] Open
Abstract
A poly (lactide-co-glycolide) (PLGA) implant was used to control the release profile of leuprolide acetate (LA) drug. The system is an in-situ polymeric precipitation system. And the formulation consisted of PLGA polymer, LA drug and N-methyl-2-pyrrolidon solvent with no additives. First, the formulation was injected into PBS solution for in-vitro studies and then it was administered to the animal models (female rats) for in-vivo release studies. The release profiles of leuprolide acetate were measured by UV spectrophotometry for a period of 28 days. The initial burst release of LA was 14% in in-vitro whereas it was 7% in in-vivo. In-vitro and in-vivo release profiles of LA had similar trends after 72 hours. However, the rate of LA release was slower in-vivo. This might be attributed to the limited diffusion process of solvent and the drug molecules. This could be due to presence of an additional pressure caused by the surrounding tissue and also the presence of small amount of water between cells in the subcutaneous site. Cross-section and surface of the implants were studied via scanning electron microscopy. Morphology of both in-vitro and in-vivo implants confirmed the release behaviours. No toxicity effects were reported in the histopathological assay. Furthermore, the pharmacological analysis showed more inactive ovaries due to release of LA.
Collapse
Affiliation(s)
- Roya Mashayekhi
- Faculty of Biomedical Engineering Department, Islamic Azad University, Science and Research Branch, Tehran, Iran
- Iran Polymer and Petrochemical Institute, P.O. Box:14185/458, Tehran, Iran
| | - Hamid Mobedi
- Iran Polymer and Petrochemical Institute, P.O. Box:14185/458, Tehran, Iran
| | | | - Marjan Enayati
- Pharmaziezentrum, Althanstrasse 14, Universität Wien, Raum 2D177, Wien, Austria
| |
Collapse
|
22
|
Regnier-Delplace C, Thillaye du Boullay O, Siepmann F, Martin-Vaca B, Demonchaux P, Jentzer O, Danède F, Descamps M, Siepmann J, Bourissou D. PLGAs bearing carboxylated side chains: Novel matrix formers with improved properties for controlled drug delivery. J Control Release 2013; 166:256-67. [DOI: 10.1016/j.jconrel.2012.12.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 12/08/2012] [Accepted: 12/18/2012] [Indexed: 01/12/2023]
|
23
|
Ghalanbor Z, Körber M, Bodmeier R. Protein release from poly(lactide-co-glycolide) implants prepared by hot-melt extrusion: Thioester formation as a reason for incomplete release. Int J Pharm 2012; 438:302-6. [DOI: 10.1016/j.ijpharm.2012.09.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2012] [Revised: 09/06/2012] [Accepted: 09/08/2012] [Indexed: 11/25/2022]
|
24
|
Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv 2012; 9:343-54. [DOI: 10.1517/17425247.2012.662484] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
25
|
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int J Pharm 2011; 415:34-52. [DOI: 10.1016/j.ijpharm.2011.05.049] [Citation(s) in RCA: 722] [Impact Index Per Article: 55.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Revised: 05/08/2011] [Accepted: 05/09/2011] [Indexed: 01/07/2023]
|
26
|
Camargo JA, Sapin A, Daloz D, Maincent P. Ivermectin-loaded microparticles for parenteral sustained release:in vitrocharacterization and effect of some formulation variables. J Microencapsul 2010; 27:609-17. [DOI: 10.3109/02652048.2010.501397] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
27
|
Khaled KA, Sarhan HA, Ibrahim MA, Ali AH, Naguib YW. Prednisolone-loaded PLGA microspheres. in vitro characterization and in vivo application in adjuvant-induced arthritis in mice. AAPS PharmSciTech 2010; 11:859-69. [PMID: 20490959 PMCID: PMC2902349 DOI: 10.1208/s12249-010-9445-5] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Accepted: 04/27/2010] [Indexed: 11/30/2022] Open
Abstract
This study aimed at preparation of a sustained-release steroidal treatment for chronic inflammatory conditions, such as rheumatoid arthritis. To achieve such a goal, biodegradable poly-lactide-co-glycolide prednisolone-loaded microspheres were prepared using o/w emulsion solvent evaporation method. Formulation parameters were adjusted so as to optimize the microsphere characteristics. The prepared microspheres exhibited smooth and intact surfaces, with average size range not exceeding 65 microm. The encapsulation efficiency percent of most microsphere formulations fell within the range of 25-68%. Drug release from these microspheres took place over 4 weeks, with near-to-zero-order patterns. Two successful formulations were chosen for the treatment of unilateral arthritis, induced in mice using Freund's complete adjuvant (FCA). Inflammatory signs of adjuvant arthritis included severe swelling of the FCA-injected limbs, in addition to many histopathological lesions. These included inflammatory cell infiltration, synovial hyperplasia, cartilage, and bone erosion. Parenteral administration of the selected formulae dramatically reduced the swelling of the FCA-injected limbs. In addition, histological examination revealed that the microsphere treatment protocol efficiently protected cartilages and bones of mice, injected with FCA initial and booster doses, from erosion. These results could not be achieved by a single prednisolone dose of 5 mg/kg.
Collapse
Affiliation(s)
- Khaled A. Khaled
- />Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt
| | - Hatem A. Sarhan
- />Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt
| | - Mohamed Abbas Ibrahim
- />Department of Pharmaceutics, Faculty of Pharmacy, King Saud University, Riyadh, 11451 Kingdom of Saudi Arabia
| | - Azza H. Ali
- />Department of Histology, Faculty of Medicine, Minia University, Minia, Egypt
| | - Youssef W. Naguib
- />Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt
| |
Collapse
|
28
|
Wang CK, Wang WY, Meyer RF, Liang Y, Winey KI, Siegel SJ. A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process. J Biomed Mater Res B Appl Biomater 2010; 93:562-72. [PMID: 20225251 DOI: 10.1002/jbm.b.31617] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Low compliance with medication is the major cause of poor outcome in schizophrenia treatment. While surgically implantable solvent-cast pellets were produced to improve outcome by increased compliance with medication, this process is laborious and time-consuming, inhibiting its broader application (Siegel et al., Eur J Pharm Biopharm 2006;64:287-293). In this study, the previous fabrication process was translated to a continuous and scalable extrusion method. Extrusion processes were modified based on in vitro release studies, drug load consistency examination, and surface morphology analysis using scanning electron microscopy. Afterward, optimized haloperidol implants were implanted into rats for preliminary analysis of biocompatibility. Barrel temperature, screw speed and resulting processing pressure influenced surface morphology and drug release. Data suggest that fewer surface pores shift the mechanism from bulk to surface PLGA degradation and longer lag period. Results demonstrate that extrusion is a viable process for manufacturing antipsychotic implants.
Collapse
Affiliation(s)
- Cheng-Kuo Wang
- Stanley Center for Experimental Therapeutics, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | |
Collapse
|
29
|
Yuan P, Huang Y, Wu H, Teng Z, Zhang J, Xin X. Induction of a local pseudo-pregnancy via levonorgestrel-loaded microspheres for the treatment of endometriosis in a rabbit model. Hum Reprod 2009; 25:462-9. [PMID: 19897855 DOI: 10.1093/humrep/dep386] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Endometriosis is a chronic disease that responds to systemic pseudo-pregnancy therapy. However, side effects limit their long-term use, and recurrence often occurs after cessation of medication. Reducing side effects whereas improving therapeutic efficacy of pseudo-pregnancy therapy seems contradictory, but appealing. In order to address this dilemma, the efficacy and side effects of local pseudo-pregnancy therapy were investigated for the first time in an endometriosis animal model. METHODS AND RESULTS Levonorgestrel-loaded polylactic acid microspheres (LNG-microspheres) were prepared by using an oil-in-water emulsification-solvent evaporation method. Rabbits with experimental endometriosis were randomized to treatment with local pseudo-pregnancy therapy, local blank microspheres, systemic pseudo-pregnancy therapy, ovariectomy or the control. Local pseudo-pregnancy was induced by injection of LNG-microspheres directly into endometrial cysts. Compared with the systemic pseudo-pregnancy group, significantly higher intra-cystic drug levels were maintained for at least 6 months with much lower serum levels in the local pseudo-pregnancy group (P < 0.01). The high intra-cystic levonorgestrel simulated a state of potent pregnancy, which induced size reductions and endometrial atrophy comparable to those of ovariectomy. Moreover, major metabolic parameters and ovarian function were not disturbed by local pseudo-pregnancy therapy. CONCLUSIONS Induction of a local pseudo-pregnancy could achieve therapeutic efficacy comparable to that of ovariectomy without provoking any marked side effects in a rabbit endometriosis model. Thus it may be a preferable option for patients with endometriosis.
Collapse
Affiliation(s)
- Peng Yuan
- Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, No. 17 Changle West Road, Xi'an, Shaan'xi 710032, China.
| | | | | | | | | | | |
Collapse
|
30
|
Schoubben A, Blasi P, Giovagnoli S, Perioli L, Rossi C, Ricci M. Novel composite microparticles for protein stabilization and delivery. Eur J Pharm Sci 2009; 36:226-34. [DOI: 10.1016/j.ejps.2008.09.008] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2008] [Revised: 09/16/2008] [Accepted: 09/21/2008] [Indexed: 11/24/2022]
|
31
|
|
32
|
Desai KGH, Mallery SR, Schwendeman SP. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur J Pharm Biopharm 2008; 70:187-98. [PMID: 18472254 DOI: 10.1016/j.ejpb.2008.03.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2007] [Revised: 03/11/2008] [Accepted: 03/12/2008] [Indexed: 10/22/2022]
Abstract
The objective of this study was to investigate the potential of various formulation strategies to achieve 1-month continuous (improved) release of the novel anti-cancer drug, 2-methoxyestradiol (2-ME), from injectable cylindrical poly(DL-lactide-co-glycolide) (PLGA) implants. PLGA implants were prepared by a solvent extrusion method. PLGA 50:50 (M(w)=51 kDa, end group=lauryl ester) (PLGA-lauryl ester) implants loaded with 3-30 wt% 2-ME exhibited a pronounced lag phase (i.e., corresponding to induction time to polymer mass loss) and triphasic release profile. Incorporation of 5 wt% hydroxypropyl-beta-cyclodextrin (HP-beta-CD) (approximately 57% release after 28 days) or Pluronic F127 (approximately 42% release after 28 days) in PLGA-lauryl ester implants reduced the lag-phase and improved the drug release moderately over a period of 28 days. The formation and the incorporation of a 2-ME/polyethylene glycol (PEG) 8000 solid dispersion in PLGA-lauryl ester implants further increased drug release (approximately 21% and 73% release after 1 and 28 days, respectively), attributable to improved drug solubility/dissolution, higher matrix porosity, and accelerated polymer degradation. Blending of PLGA 50:50 (M(w)=24 kDa, end group=COOH) (PLGA-COOH) with the PLGA-lauryl ester also provided moderate enhancement of 2-ME release over a period of 28 days. PLGA-COOH (M(w)=24 kDa) implants with 3-5% w/w pore-forming MgCO(3) exhibited the most desirable drug release among all the formulations tested, and, demonstrated 1-month slow and continuous in vitro release of approximately 80% 2-ME after a minimal initial burst. Hence, these formulation approaches provide several possible avenues to improve release rates of the hydrophobic drug, 2-ME, from PLGA for future application in regional anti-cancer therapy.
Collapse
Affiliation(s)
- Kashappa Goud H Desai
- Department of Pharmaceutical Sciences, University of Michigan, 428 Church Street, Ann Arbor, MI 48109, USA
| | | | | |
Collapse
|
33
|
Astaneh R, Nafissi-Varcheh N, Erfan M. Zinc-leuprolide complex: preparation, physicochemical characterization and release behaviour from in situ
forming implant. J Pept Sci 2007; 13:649-54. [PMID: 17726721 DOI: 10.1002/psc.894] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Leuprolide acetate (LA) has been accepted as treatment for prostatic cancer and is currently also being evaluated in phase II clinical trials for the treatment of Alzheimer's disease. In this study, the zinc complex of leuprolide was prepared and its structure determined by Fourier-transform infrared (FTIR), differential scanning calorimetry (DSC), UV, X-ray diffraction (XRD), atomic absorption spectroscopy, elemental analysis, and compared with these parameters for leuorolide acetate. Also, the in vitro release profile of leuprolide and its complex form in situ forming implant (ISFI) in comparison to a commercial formulation (Eligard) was investigated. These studies indicate that the zinc complex can be effectively synthesized and influenced on tri-phasic pattern after burst release of LA from the ISFI and shifts this trend to a continuous release profile. Non-linear regression test confirmed this transformation as a zero-order release profile as well.
Collapse
Affiliation(s)
- Reyhaneh Astaneh
- Department of Pharmaceutics, School of Pharmacy, Shaheed Beheshti University of Medical Sciences, P.O. Box 14155-6153, Tehran, Iran.
| | | | | |
Collapse
|